Comment on the article: “Diagnostic performance of the FINDRISC questionnaire to identify insulin resistance in adults”
Main Article Content
Keywords
Research, Diabetes Mellitus, Type 2, Sensitivity and Specificity
Abstract
The FINDRISC test is a scale developed in Finland by Lindström and Tuomilehto to determine a patient’s risk of developing type 2 diabetes. This scale has been accepted and valid in many countries, including Spain, Greece, Norway, and Germany. Having widely accepted instruments opens the possibility of conducting studies between different countries or cultures, which implies evaluating the various items of the instrument in the most accurate way possible. It is important to note that in Mexico, according to ENSANUT 2022, the prevalence of diagnosed diabetes was 12.6% and that of undiagnosed diabetes was 5.8%, resulting in a total prevalence of diabetes of 18.3%. In contrast, in Finland, for the year 2021, the prevalence was 7.7%, which denotes a large difference in the number of people living with diabetes in both countries.
References
Varela-Vega Y, Roy-García IA, Pérez-Rodríguez M, et al. Certeza diagnóstica del instrumento FINDRISC para identificar resistencia a la insulina en adultos. Rev Med Inst Mex Seguro Soc. 2023;61(1):33-41
Lindström J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care. 2003;26(3):725-31
Salinero-Fort MA, Burgos-Lunar C, Lahoz C, et al. SPREDIA-2 Group. Performance of the Finnish Diabetes Risk Score and a Simplified Finnish Diabetes Risk Score in a Community-Based, Cross-Sectional Programme for Screening of Undiagnosed Type 2 Diabetes Mellitus and Dysglycaemia in Madrid, Spain: The SPREDIA-2 Study. PLoS One. 2016;11(7):e0158489
Schwarz PE, Li J, Reimann M, Schutte AE, et al; The Finnish Diabetes Risk Score is associated with insulin resistance and progression towards type 2 diabetes. J Clin Endocrinol Metab. 2009;94(3):920-6.
Makrilakis K, Liatis S, Grammatikou S, et al. Validation of the Finnish diabetes risk score (FINDRISC) questionnaire for screening for undiagnosed type 2 diabetes, dysglycaemia and the metabolic syndrome in Greece. Diabetes Metab. 2011;37(2):144-151
American Diabetes Association Professional Practice Committee. Standards of medical care in diabetes-2022. Diabetes Care. 2022;45(suppl 1): S17 S38. doi: 10.2337/dc22-S002
Cerhan JR, Moore SC, Jacobs EJ, et al. A pooled analysis of waist circumference and mortality in 650,000 adults. Mayo Clinic Proceedings. 2014;89(3): 335-345. 8 American Diabetes Association: Screening for diabetes. Diabetes Care 2024;25:21S-24S
International Diabetes Federation. IDF Diabetes Atlas 10th edition. 2019. Disponible en: https://dia betesatlas.org/idfawp/resourcefiles/2021/07/IDF_ Atlas_10th_Edition_2021.pdf
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.